Inclusion Criteria:
- Depending upon study part: a history or status of a histologically-confirmed
hematological malignancy that is expected to express CD19 and CD20; relapse after or
failure to respond to at least one prior treatment regimen; and no available treatment
options that are expected to prolong survival
- Must have at least one measureable target lesion (>/= 1.5 cm) in its largest dimension
by computed tomography scan
- Able and willing to provide a fresh biopsy from a safely accessible site, per
Investigator's determination, providing the participant has more than one measurable
target lesion
- Eastern Cooperative Oncology Group performance status of 0 or 1
- Life expectancy of >/= 12 weeks
- Adverse events from prior anti-cancer therapy must have resolved to Grade </= 1
- Adequate liver, haematological, and renal function
- Negative test results for acute or chronic hepatitis B virus infection
- Negative test results for hepatitis C virus and HIV
- Negative serum pregnancy test within 7 days prior to first dose of obinutuzumab in
women of childbearing potential. Women who are not of childbearing potential or
surgically sterile are not required to have a pregnancy test
- Participants must agree to either remain completely abstinent or to use two effective
contraceptive methods that result in a failure rate of <1% per year from screening
until a) at least 3 months after pre-treatment with obinutuzumab or 2 months after the
last dose of RO7227166, whichever is longer, if the participant is a male or b) until
at least 18 months after pre-treatment with obinutuzumab or 2 months after the last
dose of RO7227166, whichever is longer
Exclusion Criteria:
- Participants with lymphomatous bone marrow involvement at baseline as detected by
histology or cytology.
- Circulating lymphoma cells, defined by out of range (high) absolute lymphocyte count
or the presence of abnormal cells in the peripheral blood differential signifying
circulating lymphoma cells
- Participants with acute bacterial, viral, or fungal infection at baseline, confirmed
by a positive blood culture within 72 hours prior to obinutuzumab infusion or by
clinical judgment in the absence of a positive blood culture
- Participants with known active infection, or reactivation of a latent infection,
whether bacterial, viral fungal, mycobacterial, or other pathogens (excluding fungal
infections of nail beds) or any major episode of infection requiring hospitalization
or treatment with IV antibiotics
- Pregnant or breast-feeding or intending to become pregnant during the study
- Prior treatment with systemic immunotherapeutic agents, including, but not limited to,
radio-immunoconjugates, antibody-drug conjugates, immune/cytokines or monoclonal
antibodies within 4 weeks or five half-lives of the drug, whichever is longer, before
obinutuzumab infusion on D-7
- History of treatment-emergent immune-related AEs associated with prior
immunotherapeutic agents and auto-immune disease
- Treatment with standard radiotherapy, any chemotherapeutic agent, or treatment with
any other investigational anti-cancer agent within 4 weeks prior to obinutuzumab
infusion
- Prior solid organ transplantation
- Prior allogeneic stem cell transplant (SCT) and prior chimeric antigen receptor
-T-cell therapy
- Autologous SCT within 100 days prior to obinutuzumab infusion
- History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
and confirmed progressive multifocal leukoencephalopathy
- Current or past history of central nervous system (CNS) lymphoma and CNS disease
- Evidence of significant, uncontrolled concomitant diseases that could affect
compliance with the protocol or interpretation of results, including diabetes
mellitus, history of relevant pulmonary disorders and known autoimmune diseases
- Major surgery or significant traumatic injury < 28 days prior to the Gpt infusion or
anticipation of the need for major surgery during study treatment
- Participants with another invasive malignancy in the last 2 years
- Significant cardiovascular disease
- Administration of a live, attenuated vaccine within 4 weeks before Gpt infusion or
anticipation that such a live attenuated vaccine will be required during the study
- Received systemic immunosuppressive medications with the exception of corticosteroid
treatment < =25 mg/day prednisone or equivalent within 2 weeks prior to Gpt infusion.
Inhaled and topical steroids are permitted
